Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2785–2808 of 6,604 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Bursitis, Tendonitis, Shoulder Pain
Interventions: MRX-7EAT; Drug
Lead sponsor: MEDRx USA, Inc.; Industry
Eligibility: 14 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 27
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 23 more

Conditions: T1DM - Type 1 Diabetes Mellitus
Interventions: 13 CGM (continuous glucose monitor); Device
Lead sponsor: Sinocare; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Lymphoma, Non-Hodgkin
Interventions: TRAIL-R1 mAb (TRM-1; HGS-ETR1); Drug
Lead sponsor: Human Genome Sciences Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 7
States / cities: Rochester, Minnesota • Omaha, Nebraska • Buffalo, New York + 4 more

Conditions: Severe Traumatic Brain Injury
Interventions: Not listed
Lead sponsor: Corewell Health West; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Multiple Sclerosis, Myasthenia Gravis, Transverse Myelitis
Interventions: Blood Draw, Cheek swab; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2031
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Indacaterol 75 μg, Placebo to indacaterol; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 62
States / cities: Peoria, Arizona • Pine Bluff, Arkansas • Buena Park, California + 57 more

Conditions: Moderate or Severe Hypoxic-ischemic Encephalopathy in Newborns
Interventions: Infusion of autologous cord blood, Placebo; Biological
Lead sponsor: Michael Cotten; Other
Eligibility: 0 Hours to 6 Hours
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Arthroplasty, Replacement, Hip
Interventions: Trident® Tritanium™ Acetabular Shell; Device
Lead sponsor: Stryker Orthopaedics; Industry
Eligibility: 21 Years to 85 Years
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 15
States / cities: Orange, California • Jacksonville, Florida • Miami, Florida + 11 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin Glulisine, Insulin Glargine, Premixed Insulin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 588 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Alzheimer's Disease
Interventions: TC-5619, Placebo; Drug
Lead sponsor: Targacept Inc.; Industry
Eligibility: 55 Years to 80 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 10
States / cities: Long Beach, California • San Francisco, California • Hallandale, Florida + 7 more

Conditions: Chronic Heart Failure
Interventions: AZD5462, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 14
States / cities: Alexander City, Alabama • Northridge, California • Torrance, California + 11 more

Conditions: Sleep Apnea, Obstructive
Interventions: Seltorexant 40 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 4
States / cities: Atlanta, Georgia • New York, New York • Cincinnati, Ohio + 1 more

Conditions: Gastric Cancer, Gastrointestinal Cancer, HER2 Gene Mutation
Interventions: Neratinib Pill, Fam-Trastuzumab Deruxtecan-Nxki (TDxD); Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 3
States / cities: Palo Alto, California • Buffalo, New York • Philadelphia, Pennsylvania

Conditions: Skin Wrinkling
Interventions: Emervel Classic Lidocaine, Juvederm® Ultra; Device
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 12
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 8 more

Conditions: Venous Leg Ulcer
Interventions: AutoloGel; Device
Lead sponsor: Cytomedix; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Arcadia, California • Cumming, Georgia

Conditions: Prostate Cancer
Interventions: Degarelix, Goserelin acetate; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 8
States / cities: Aurora, Colorado • Denver, Colorado • Dover, Delaware + 5 more

Conditions: Kidney Cancer, Renal Cell Carcinoma
Interventions: HSPPC-96; Biological
Lead sponsor: Agenus Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 5
States / cities: San Francisco, California • Stanford, California • Hackensack, New Jersey + 2 more

Conditions: Breast Cancer
Interventions: gemcitabine/carboplatin, Iniparib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 519 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 102
States / cities: Birmingham, Alabama • Sedona, Arizona • Jonesboro, Arkansas + 98 more

Conditions: HIV Infections
Interventions: DTG film-coated tablets, DTG granules for suspension, DTG dispersible tablets; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 4 Weeks to 17 Years
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2023
U.S. locations: 17
States / cities: La Jolla, California • Long Beach, California • Los Angeles, California + 11 more

Conditions: MASH - Metabolic Dysfunction-Associated Steatohepatitis, Heart Failure With Preserved Ejection Fraction (HFPEF)
Interventions: Resmetirom, Placebo; Drug
Lead sponsor: Madrigal Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: Peoria, Arizona • Oxnard, California • Fort Myers, Florida + 2 more

Conditions: Aneurysmal Subarachnoid Hemorrhage
Interventions: Clazosentan 1 mg/h, Clazosentan 5 mg/h, Clazosentan 15 mg/h, Placebo; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 10
States / cities: Peoria, Illinois • Indianapolis, Indiana • Baltimore, Maryland + 6 more

Conditions: Breast Cancer
Interventions: Ultrahypofractionated Radiation, Moderately Hypofractionated Radiation; Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 768 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 5
States / cities: Loveland, Colorado • Jacksonville, Florida • Voorhees Township, New Jersey + 2 more

Conditions: X-Linked Retinitis Pigmentosa
Interventions: AAV5-RPGR; Genetic
Lead sponsor: MeiraGTx UK II Ltd; Industry
Eligibility: 5 Years and older · Male only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 3
States / cities: Boston, Massachusetts • Ann Arbor, Michigan • Pittsburgh, Pennsylvania

Conditions: Osteoarthritis
Interventions: Oral Salmon Calcitonin, Oral Salmon Calcitonin (Placebo); Drug
Lead sponsor: Nordic Bioscience A/S; Industry
Eligibility: 51 Years to 80 Years
Enrollment: 1,030 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 6
States / cities: Tuscaloosa, Alabama • Sacramento, California • Chicago, Illinois + 3 more

Search by objective public record fields.

Safety & Efficacy Study of MRX-7EAT Patch in the Treatment of Pain of the Shoulder

The True Vie I3 Continuous Glucose Monitoring System in Pediatric Patients With Type 1 Diabetes Mellitus

Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

The Systemic Nature of Severe Traumatic Brain Injury

Serum Auto-Antibodies in Neurological Diseases

12-week Efficacy of Indacaterol

A Multi-site Study of Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy

Trident® Tritanium™ Acetabular Shell Revision Study

Insulin Glargine "All to Target" Trial

Multiple Ascending Dose Study of TC-5619 in Healthy Elderly Subjects and Subjects With Alzheimer's Disease

A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure

A Study to Assess the Effect of Seltorexant Compared to Placebo on Respiration During Sleep in Adult Participants With Obstructive Sleep Apnea

Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients

Emervel Classic Lidocaine Versus Juvederm® Ultra in Treatment of Moderate to Severe Facial Wrinkles and Folds

A Cohort Trial Comparing AutoloGel Therapy to Usual and Customary Care in Venous Leg Ulcers

A Degarelix Trial in Patients With Prostate Cancer

Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney Cancer

A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer

Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents

Resmetirom in Patients With MASH and HFpEF

Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)

Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer

Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR)

Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis (OA 2 Study)